VIATRIS INC

VTRS is the ticker symbol for Viatris Inc., a global pharmaceutical company listed on the Nasdaq Global Select Market. The stock represents an ownership stake in a company formed through the combination of Mylan and Pfizer's Upjohn business in 2020. Viatris develops, manufactures, and distributes a broad portfolio of medicines, including generics, branded drugs, and over-the-counter products. Trading under VTRS gives investors exposure to a healthcare company with operations across more than 150 countries.

The current price of VTRS changes continuously during market hours and can be affected by news, earnings, and broader market conditions. To see the latest price, check the quote displayed on this VTRS stock detail page, which typically includes the most recent trade, daily change, and volume. For the most up-to-date figures, refresh the page or look at the real-time price shown at the top of the page.

Evaluating VTRS involves comparing its market price to fundamental metrics such as earnings, revenue, and cash flow. Common tools include the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-EBITDA (EV/EBITDA). Investors may also compare these metrics with peers in the pharmaceutical and generic drug sectors. Since valuation can vary by market conditions, the latest VTRS metrics shown on this page provide a current starting point for analysis.

You can buy VTRS through a brokerage account, either online or through a full-service broker. The process involves opening an account, funding it, and placing a buy order for VTRS shares. Orders can be market orders, which execute at the current price, or limit orders, which specify a maximum price. Fractional shares may be available depending on the broker. Always verify trading fees and whether the broker offers access to Nasdaq-listed stocks like VTRS.

Viatris has historically paid a quarterly dividend to shareholders, though the exact amount and schedule can change based on company policy and financial performance. For the most current dividend information, including the latest declared amount and payment date, refer to the dividend section on this VTRS page. Dividend eligibility depends on owning shares before the ex-dividend date, and investors should consider payout sustainability when evaluating VTRS.

VTRS faces risks such as pricing pressure in generic drugs, regulatory changes, patent expirations, and competition from other pharmaceutical companies. Global operations expose it to currency fluctuations, geopolitical events, and varying healthcare policies. Additionally, high debt levels from its formation could affect financial flexibility. These factors can influence earnings and stock performance, so monitoring company reports and industry news is important for understanding the risk profile of VTRS.